ALK and lymphoma: Finally, the same approach was recently developed in the context of ALK-positive lymphoma: three groups described degraders of ALK kinase based on phenylamino-pyrimidine ALK inhibitors (NVP-TAE684 or ceritinib) and either pomalidomide (compounds 9, 10, 11, 12 [202]; compounds MS4077 and MS4078 [200]) or a different von Hippel-Lindau ligand (TD-004 [201]).